Key Developments: Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

1.30USD
24 Dec 2014
Price Change (% chg)

$-0.03 (-2.26%)
Prev Close
$1.33
Open
$1.33
Day's High
$1.33
Day's Low
$1.30
Volume
14,294
Avg. Vol
48,223
52-wk High
$4.33
52-wk Low
$1.09

Search Stocks

Latest Key Developments (Source: Significant Developments)

Athersys Inc announces results from phase 2 study of multistem cell therapy for Ulcerative Colitis conducted by Pfizer Inc
Monday, 28 Apr 2014 07:00am EDT 

Athersys Inc:Announces interim results from the phase 2 clinical study of the administration of Athersys' MultiStem cell therapy to treatment refractory ulcerative colitis (UC) patients being conducted by Pfizer, Inc.Study results demonstrate favorable safety and tolerability for MultiStem through 8 weeks following treatment.However, the cell therapy failed to show meaningful benefit, following a single administration, in patients suffering from chronic, moderate-to-severe UC who have failed other therapies.These results reflect patient data 8 weeks following cell therapy or placebo administration and include the primary efficacy endpoints for the study.  Full Article

Athersys Inc prices registered direct offering of common stock and warrants
Friday, 10 Jan 2014 09:31am EST 

Athersys Inc:Says it has entered into definitive agreements to sell 5,000,000 shares of common stock and warrants to purchase up to 1,500,000 shares of common stock, in an offering with gross proceeds of about $20.5 mln.Says warrants are immediately exercisable.Says warrants have an exercise price of $4.50 per share of common stock and expire on July 15, 2016.Says each share of common stock, along with a warrant to purchase up to 0.30 shares of common stock, was offered for a purchase price of $4.10.Says use of net proceeds for working capital and general corporate purposes.  Full Article

Athersys Inc Enters Into Common Stock Purchase Agreement With Aspire Capital Fund, LLC-Form 8-K
Wednesday, 23 Oct 2013 08:51am EDT 

Athersys Inc reported in its Form 8-K that on October 22, 2013, the Company entered into a common stock purchase agreement (the Purchase Agreement) with Aspire Capital Fund, LLC, an Illinois limited liability company (Aspire Capital), which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $25.0 million of shares of the Company’s common stock over the 24-month term of the Purchase Agreement. In consideration for entering into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, the Company issued to Aspire Capital 333,333 shares of its common stock (the Commitment Shares). Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with Aspire Capital (the Registration Rights Agreement), pursuant to which the Company agreed to file one or more registration statements, as permissible and necessary to register under the Securities Act of 1933, as amended (the Securities Act), the sale of the shares of the Company’s common stock that have been and may be issued to Aspire Capital under the Purchase Agreement.  Full Article

Search Stocks